Navigation Links
Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
Date:6/27/2011

to have reached a rapid resolution of the GAO protest so that all parties can continue with the important work of developing smallpox antivirals," said Kenneth I. Moch, President & CEO of Chimerix.  "Chimerix is intensely focused on developing CMX001, for its dual-use potential and as a potent broad spectrum antiviral, to address the threat of smallpox release and the critical needs of immunosuppressed transplant and oncology patients with life-threatening viral infections."

About CMX001

CMX001 is being developed as a potential broad spectrum oral antiviral for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases, including herpes viruses, adenoviruses and orthopox viruses.  The growing body of evidence of CMX001's antiviral activity against all five families of dsDNA viruses that cause morbidity and mortality in humans, including smallpox, has strengthened the compound's potential as a dual-use product prescribed as a traditional pharmaceutical and stockpiled as a biodefense countermeasure. More than 500 patients have been dosed with CMX001 to date in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of dsDNA viral diseases.  250 patients have received CMX001 under Emergency Investigational New Drug Applications (EINDs), including for treatment of orthopox viruses.  A significant number of the individuals receiving CMX001 in human testing have been immunocompromised as a result of disease or immunosuppressing therapies associated with stem cell or solid organ transplantation.

Clinical studies of CMX001 include: an ongoing Phase 2 study of the prevention/control of cytomegalovirus (a herpes virus) in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study currently being initiated for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chimerix to Present at Two Upcoming Investor Conferences
2. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
3. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
4. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
5. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
6. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Initiates Phase 1 Study of CMX157
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
11. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... results for the three months ended March 31, 2015 ... amounts are in Canadian dollars. Effective ... end from May 31 to December 31. As a ... reported is for the three months ended March 31, ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. Macromolecules ... acids undergo separation or are broken into ... biotechnological products. This separation requires various advanced ...
(Date:5/5/2015)... , May 5, 2015 Reprints Desk, ... in providing on-demand access to scientific, technical and medical ... with the Association of Southeastern Research Libraries (ASERL) ... research libraries located across 11 southeastern states. Founded in ... and collaborative programs to address the continually changing needs ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... Live Webcast from the Palace Hotel in San Francisco on Wednesday, ... ... 10th, SAN DIEGO, Oct. 2 Favrille, Inc. (Nasdaq:,FVRL), ... today announced that Tamara,Seymour, Chief Financial Officer, will present at the ...
... 454 Life Sciences, a Roche,company, and Perlegen Sciences, ... genetic re-sequencing in hundreds of DNA samples,collected by ... widely,prescribed class of drug. The goal of the ... can be identified and,validated to create a clinical ...
... SAFC(R), a member of the,Sigma-Aldrich(TM) Group (Nasdaq: ... to begin,construction of a new cGMP potent ... Pharma sector,s St. Louis manufacturing campus.,This addition ... requirements,that demand a combination of small molecule ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 2SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... certain materials, researchers have grown carbon nanotubes that are ... than 2 centimeters long, each nanotube is 900,000 times ... potential to be longer, stronger and better conductors of ... use in smart fabrics, sensors and a host of ...
... An international team, led by researchers at the Broad ... National Institutes of Health (NIH), today announced the publication ... a South American species of opossum. In a comparison ... human, published in the May 10 issue of the ...
... of tissue-engineered scaffolding made of cartilage cells, which have ... cartilage tissue. Cartilage cells are extracted and seeded to ... new cartilage tissue is grown along the structure. The ... procedure was extremely successful in tested mice as the ...
Cached Biology News:The longest carbon nanotubes you've ever seen 2Researchers publish first marsupial genome sequence 2Researchers publish first marsupial genome sequence 3
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Request Info...
Myt 1 (N-17)...
... are functionally defined by their capacity to ... into multiple specialized progenitor cells, which can ... Neural stem cells (NSCs) are capable of ... neurons and oligodendrocytes. During the isolation and ...
Biology Products: